The McConnell Group Inc.

Dublin, PA, United States

The McConnell Group Inc.

Dublin, PA, United States
SEARCH FILTERS
Time filter
Source Type

Grubman M.J.,U.S. Department of Agriculture | Moraes M.P.,U.S. Department of Agriculture | Schutta C.,Plum Island Animal Disease Center | Barrera J.,The McConnell Group Inc. | And 5 more authors.
Future Virology | Year: 2010

The results of the first decade of the development of a replication-defective human adenovirus serotype 5 (Ad5) containing the capsid-and 3C protease-coding regions of foot-and-mouth disease (FMD) virus as a vaccine candidate are presented. In proof-of-concept studies, it was demonstrated that a single inoculation with this vaccine vector containing the capsid of FMD virus A24 Cruzeiro protected both swine and cattle following homologous challenge by direct inoculation 1 week postvaccination. We have expanded these studies in cattle with larger numbers of animals and by testing the vaccine in direct-contact challenge studies, including its ability to prevent FMD virus shedding and transmission. Furthermore, we have developed manufacturing protocols to allow the scalable production of these FMD molecular vaccine products for US Department of Agriculture licensure approval and availability for inclusion in the US National Veterinary Stockpile. We have also constructed and initiated cattle efficacy testing of Ad5 vectors containing the capsid-coding regions from other FMD virus serotypes and subtypes, as well as initiated studies to improve FMD molecular vaccine potency. © 2010 Future Medicine Ltd.

Loading The McConnell Group Inc. collaborators
Loading The McConnell Group Inc. collaborators